Jan C. Fagerberg
Nessuna posizione attualmente
Profilo
Jan C.
Fagerberg served as the Chief Medical Officer & SVP at Amgen Rockville, Inc. from 2009 to 2011.
Prior to that, he was the Medical Director at Topotarget A in 2009.
He also served as an Independent Director at Response Genetics, Inc. in 2010 and 2011.
Fagerberg earned a doctorate degree from Karolinska Institutet in 1988.
Precedenti posizioni note di Jan C. Fagerberg
| Società | Posizione | Fine |
|---|---|---|
| RESPONSE GENETICS, INC | Director/Board Member | 12/10/2011 |
| TOPOTARGET A/S | Chief Tech/Sci/R&D Officer | 01/01/2009 |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Chief Tech/Sci/R&D Officer | - |
Formazione di Jan C. Fagerberg
| Karolinska Institutet | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| RESPONSE GENETICS, INC | Health Technology |
| Aziende private | 2 |
|---|---|
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
- Borsa valori
- Insiders
- Jan C. Fagerberg
